DLBCL
Haematology · 2019–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| loncastuximab tesirine Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received two or more prior lines of therapy. | Mar 2026 | Not recommended | input received Rare Cancers Australia · Lymphoma Group |
| glofitamab Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after one or more lines of systemic therapy who are unable to… | Jul 2025 | Recommended with restriction | input received Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia |
| polatuzumab vedotin Treatment of diffuse large B-cell lymphoma (DLBCL) in previously untreated patients with an international prognostic index (IPI) score of 3–5, in combination… | Mar 2025 | Recommended with restriction | input received Lymphoma Group · Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia |
| epcoritamab Treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy who have previously… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · Leukaemia Foundation |
| polatuzumab vedotin Previously untreated diffuse large B-cell lymphoma (DLBCL) with an international prognostic index (IPI) score of 3-5, in combination with rituximab,… | Nov 2022 | Not recommended | input received Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| selinexor Treatment of adult patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. | Jul 2021 | Not recommended | input received Rare Cancers Australia · Lymphoma Australia · Leukaemia Foundation · Eastern Cooperative Oncology Group |
| polatuzumab vedotin Treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in combination with bendamustine and rituximab in patients ineligible for stem… | Nov 2019 | Not recommended | 2 individuals |
Who spoke
Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia · Lymphoma Group · Eastern Cooperative Oncology Group
What the PBS pays
$10M in government benefit over 2024–25, across 952 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| selinexor | $8.6M |
| epcoritamab | $1.2M |
Appraised elsewhere
NICE, in England and Wales, has appraised 9 technologies for this condition, recommending 7 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| glofitamabGlofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | TA1113 | recommended | 2025-12 |
| lisocabtagene maraleucelLisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | recommended | 2025-03 |
| epcoritamabEpcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | recommended restricted | 2024-03 |
| tisagenlecleucelTisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | terminated | 2023-11 |
| glofitamabGlofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | recommended restricted | 2023-10 |
| axicabtagene ciloleucelAxicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | recommended | 2023-06 |
| tafasitamabTafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | not recommended | 2023-05 |
| polatuzumab vedotinPolatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | recommended restricted | 2023-03 |
| polatuzumab vedotinPolatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | recommended restricted | 2020-09 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.